127 related articles for article (PubMed ID: 37993104)
41. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
42. DM1 CTG expansions affect insulin receptor isoforms expression in various tissues of transgenic mice.
Guiraud-Dogan C; Huguet A; Gomes-Pereira M; Brisson E; Bassez G; Junien C; Gourdon G
Biochim Biophys Acta; 2007 Dec; 1772(11-12):1183-91. PubMed ID: 17950578
[TBL] [Abstract][Full Text] [Related]
43. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2.
Timchenko L
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405
[TBL] [Abstract][Full Text] [Related]
44. Differences in splicing defects between the grey and white matter in myotonic dystrophy type 1 patients.
Nishi M; Kimura T; Igeta M; Furuta M; Suenaga K; Matsumura T; Fujimura H; Jinnai K; Yoshikawa H
PLoS One; 2020; 15(5):e0224912. PubMed ID: 32407311
[TBL] [Abstract][Full Text] [Related]
45. Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice.
Oana K; Oma Y; Suo S; Takahashi MP; Nishino I; Takeda S; Ishiura S
Sci Rep; 2013; 3():2142. PubMed ID: 23828222
[TBL] [Abstract][Full Text] [Related]
46. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy.
Lueck JD; Mankodi A; Swanson MS; Thornton CA; Dirksen RT
J Gen Physiol; 2007 Jan; 129(1):79-94. PubMed ID: 17158949
[TBL] [Abstract][Full Text] [Related]
47. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
48. Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes.
Kim EY; Barefield DY; Vo AH; Gacita AM; Schuster EJ; Wyatt EJ; Davis JL; Dong B; Sun C; Page P; Dellefave-Castillo L; Demonbreun A; Zhang HF; McNally EM
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30730308
[TBL] [Abstract][Full Text] [Related]
49. RBFOX1 cooperates with MBNL1 to control splicing in muscle, including events altered in myotonic dystrophy type 1.
Klinck R; Fourrier A; Thibault P; Toutant J; Durand M; Lapointe E; Caillet-Boudin ML; Sergeant N; Gourdon G; Meola G; Furling D; Puymirat J; Chabot B
PLoS One; 2014; 9(9):e107324. PubMed ID: 25211016
[TBL] [Abstract][Full Text] [Related]
50. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.
Savkur RS; Philips AV; Cooper TA
Nat Genet; 2001 Sep; 29(1):40-7. PubMed ID: 11528389
[TBL] [Abstract][Full Text] [Related]
51. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
52. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
[TBL] [Abstract][Full Text] [Related]
53. Splicing biomarkers of disease severity in myotonic dystrophy.
Nakamori M; Sobczak K; Puwanant A; Welle S; Eichinger K; Pandya S; Dekdebrun J; Heatwole CR; McDermott MP; Chen T; Cline M; Tawil R; Osborne RJ; Wheeler TM; Swanson MS; Moxley RT; Thornton CA
Ann Neurol; 2013 Dec; 74(6):862-72. PubMed ID: 23929620
[TBL] [Abstract][Full Text] [Related]
54. Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1.
Leroy O; Wang J; Maurage CA; Parent M; Cooper T; Buée L; Sergeant N; Andreadis A; Caillet-Boudin ML
Biochim Biophys Acta; 2006 Apr; 1762(4):460-7. PubMed ID: 16487687
[TBL] [Abstract][Full Text] [Related]
55. Comparative transcriptional and biochemical studies in muscle of myotonic dystrophies (DM1 and DM2).
Salvatori S; Furlan S; Fanin M; Picard A; Pastorello E; Romeo V; Trevisan CP; Angelini C
Neurol Sci; 2009 Jun; 30(3):185-92. PubMed ID: 19326042
[TBL] [Abstract][Full Text] [Related]
56. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Klein AF; Gasnier E; Furling D
Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
[TBL] [Abstract][Full Text] [Related]
57. Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1.
Voellenkle C; Perfetti A; Carrara M; Fuschi P; Renna LV; Longo M; Sain SB; Cardani R; Valaperta R; Silvestri G; Legnini I; Bozzoni I; Furling D; Gaetano C; Falcone G; Meola G; Martelli F
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010208
[TBL] [Abstract][Full Text] [Related]
58. A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle.
Gudde AE; González-Barriga A; van den Broek WJ; Wieringa B; Wansink DG
Hum Mol Genet; 2016 Apr; 25(8):1648-62. PubMed ID: 26908607
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes.
Dastidar S; Majumdar D; Tipanee J; Singh K; Klein AF; Furling D; Chuah MK; VandenDriessche T
Mol Ther; 2022 Jan; 30(1):75-91. PubMed ID: 34371182
[TBL] [Abstract][Full Text] [Related]
60. Endoplasmic reticulum stress in myotonic dystrophy type 1 muscle.
Ikezoe K; Nakamori M; Furuya H; Arahata H; Kanemoto S; Kimura T; Imaizumi K; Takahashi MP; Sakoda S; Fujii N; Kira J
Acta Neuropathol; 2007 Nov; 114(5):527-35. PubMed ID: 17661063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
